Skip to main content

Bruker Forms New Chemical Analysis Division

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker today announced that has created a new Chemical Analysis division, which will operate under its Bruker Daltonics subsidiary.

The new division is the result of a recent agreement with Agilent Technologies, under which Bruker is acquiring certain product lines of Varian. The sale of the Varian assets is a condition of obtaining regulatory clearance for Agilent's $1.5 billion acquisition of Varian.

The Varian product lines being acquired — which includes inductively coupled plasma mass spectrometry instruments, laboratory gas chromatography instruments, and gas chromatography triple-quadrupole mass spectrometry instruments — will become part of the new Chemical Analysis division, said, Bruker.

"These three businesses offer an opportunity to leverage our existing strengths in the analytical instruments market … [and] will form the core offerings of our new Chemical Analysis division," Bruker President and CEO Frank Laukien said in a statement.

The firm also announced that Collin D'Silva will lead the new division as president. He previously served as CEO of Transgenomic from 1997 to 2006, and has been a director of Bruker since 2000.

As reported earlier this week by GenomeWeb Daily News, D'Silva resigned his position on Bruker's audit committee as of March 9. The firm also said today that he has stepped down from the company's board of directors as of the end of March. As a result, Bruker currently is not in compliance with Nasdaq regulations, though it said that it intends to regain compliance within the applicable 180-day cure period.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.